Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

CATACOMB: An endogenous inducible gene that antagonizes H3K27 methylation activity of Polycomb repressive complex 2 via an H3K27M-like mechanism.

Piunti A, Smith ER, Morgan MAJ, Ugarenko M, Khaltyan N, Helmin KA, Ryan CA, Murray DC, Rickels RA, Yilmaz BD, Rendleman EJ, Savas JN, Singer BD, Bulun SE, Shilatifard A.

Sci Adv. 2019 Jul 3;5(7):eaax2887. doi: 10.1126/sciadv.aax2887. eCollection 2019 Jul.

2.

Regulation of MLL/COMPASS stability through its proteolytic cleavage by taspase1 as a possible approach for clinical therapy of leukemia.

Zhao Z, Wang L, Volk AG, Birch NW, Stoltz KL, Bartom ET, Marshall SA, Rendleman EJ, Nestler CM, Shilati J, Schiltz GE, Crispino JD, Shilatifard A.

Genes Dev. 2019 Jan 1;33(1-2):61-74. doi: 10.1101/gad.319830.118. Epub 2018 Dec 20.

3.

TET2 coactivates gene expression through demethylation of enhancers.

Wang L, Ozark PA, Smith ER, Zhao Z, Marshall SA, Rendleman EJ, Piunti A, Ryan C, Whelan AL, Helmin KA, Morgan MA, Zou L, Singer BD, Shilatifard A.

Sci Adv. 2018 Nov 7;4(11):eaau6986. doi: 10.1126/sciadv.aau6986. eCollection 2018 Nov.

4.

Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced Cancer Therapy.

Liang K, Smith ER, Aoi Y, Stoltz KL, Katagi H, Woodfin AR, Rendleman EJ, Marshall SA, Murray DC, Wang L, Ozark PA, Mishra RK, Hashizume R, Schiltz GE, Shilatifard A.

Cell. 2018 Oct 18;175(3):766-779.e17. doi: 10.1016/j.cell.2018.09.027.

PMID:
30340042
5.

USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia.

Jin Q, Martinez CA, Arcipowski KM, Zhu Y, Gutierrez-Diaz BT, Wang KK, Johnson MR, Volk AG, Wang F, Wu J, Grove C, Wang H, Sokirniy I, Thomas PM, Goo YA, Abshiru NA, Hijiya N, Peirs S, Vandamme N, Berx G, Goosens S, Marshall SA, Rendleman EJ, Takahashi YH, Wang L, Rawat R, Bartom ET, Collings CK, Van Vlierberghe P, Strikoudis A, Kelly S, Ueberheide B, Mantis C, Kandela I, Bourquin JP, Bornhauser B, Serafin V, Bresolin S, Paganin M, Accordi B, Basso G, Kelleher NL, Weinstock J, Kumar S, Crispino JD, Shilatifard A, Ntziachristos P.

Clin Cancer Res. 2019 Jan 1;25(1):222-239. doi: 10.1158/1078-0432.CCR-18-1740. Epub 2018 Sep 17.

PMID:
30224337
6.

Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy.

Wang L, Zhao Z, Ozark PA, Fantini D, Marshall SA, Rendleman EJ, Cozzolino KA, Louis N, He X, Morgan MA, Takahashi YH, Collings CK, Smith ER, Ntziachristos P, Savas JN, Zou L, Hashizume R, Meeks JJ, Shilatifard A.

Nat Med. 2018 Jun;24(6):758-769. doi: 10.1038/s41591-018-0034-6. Epub 2018 May 21.

7.

An Mll4/COMPASS-Lsd1 epigenetic axis governs enhancer function and pluripotency transition in embryonic stem cells.

Cao K, Collings CK, Morgan MA, Marshall SA, Rendleman EJ, Ozark PA, Smith ER, Shilatifard A.

Sci Adv. 2018 Jan 31;4(1):eaap8747. doi: 10.1126/sciadv.aap8747. eCollection 2018 Jan.

8.

A cryptic Tudor domain links BRWD2/PHIP to COMPASS-mediated histone H3K4 methylation.

Morgan MAJ, Rickels RA, Collings CK, He X, Cao K, Herz HM, Cozzolino KA, Abshiru NA, Marshall SA, Rendleman EJ, Sze CC, Piunti A, Kelleher NL, Savas JN, Shilatifard A.

Genes Dev. 2017 Oct 1;31(19):2003-2014. doi: 10.1101/gad.305201.117.

9.

Histone H3K4 monomethylation catalyzed by Trr and mammalian COMPASS-like proteins at enhancers is dispensable for development and viability.

Rickels R, Herz HM, Sze CC, Cao K, Morgan MA, Collings CK, Gause M, Takahashi YH, Wang L, Rendleman EJ, Marshall SA, Krueger A, Bartom ET, Piunti A, Smith ER, Abshiru NA, Kelleher NL, Dorsett D, Shilatifard A.

Nat Genet. 2017 Nov;49(11):1647-1653. doi: 10.1038/ng.3965. Epub 2017 Oct 2.

10.

Histone H3K4 methylation-dependent and -independent functions of Set1A/COMPASS in embryonic stem cell self-renewal and differentiation.

Sze CC, Cao K, Collings CK, Marshall SA, Rendleman EJ, Ozark PA, Chen FX, Morgan MA, Wang L, Shilatifard A.

Genes Dev. 2017 Sep 1;31(17):1732-1737. doi: 10.1101/gad.303768.117. Epub 2017 Sep 22.

11.

PAF1 regulation of promoter-proximal pause release via enhancer activation.

Chen FX, Xie P, Collings CK, Cao K, Aoi Y, Marshall SA, Rendleman EJ, Ugarenko M, Ozark PA, Zhang A, Shiekhattar R, Smith ER, Zhang MQ, Shilatifard A.

Science. 2017 Sep 22;357(6357):1294-1298. doi: 10.1126/science.aan3269. Epub 2017 Aug 31.

12.

SET1A/COMPASS and shadow enhancers in the regulation of homeotic gene expression.

Cao K, Collings CK, Marshall SA, Morgan MA, Rendleman EJ, Wang L, Sze CC, Sun T, Bartom ET, Shilatifard A.

Genes Dev. 2017 Apr 15;31(8):787-801. doi: 10.1101/gad.294744.116. Epub 2017 May 9.

13.

Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.

Piunti A, Hashizume R, Morgan MA, Bartom ET, Horbinski CM, Marshall SA, Rendleman EJ, Ma Q, Takahashi YH, Woodfin AR, Misharin AV, Abshiru NA, Lulla RR, Saratsis AM, Kelleher NL, James CD, Shilatifard A.

Nat Med. 2017 Apr;23(4):493-500. doi: 10.1038/nm.4296. Epub 2017 Feb 27.

Supplemental Content

Loading ...
Support Center